A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Sponsor
Pharmacia and Upjohn (Industry)
Overall Status
Completed
CT.gov ID
NCT00002236
Collaborator
(none)
32
6
5.3

Study Details

Study Description

Brief Summary

The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.

Study Design

Study Type:
Interventional
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label, Parallel Group, Pilot Study of Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate, Zidovudine, and Indinavir Sulfate in HIV-1 Infected Individuals

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    You may be eligible for this study if you:
    • Are HIV-positive.

    • Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.

    • Have a CD4 cell count of at least 50 cells/mm3.

    • Are at least 14 years old (consent of parent or guardian is required if under 18).

    Exclusion Criteria

    You will not be eligible for this study if you:
    • Have ever taken an anti-HIV drug other than ZDV.

    • Have taken ZDV for more than 1 month.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AIDS Healthcare Foundation Los Angeles California United States 90027
    2 UCSF AIDS Research Institute San Francisco California United States 94105
    3 Saint Luke's - Roosevelt Hosp Ctr New York New York United States 10019
    4 Anderson Clinical Research Pittsburgh Pennsylvania United States 15213
    5 Univ of Tennessee / Div of Infect Dis / Dept of Med Memphis Tennessee United States 38165
    6 Infectious Disease Physicians Inc Annandale Virginia United States 22203

    Sponsors and Collaborators

    • Pharmacia and Upjohn

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002236
    Other Study ID Numbers:
    • 228G
    • M/3331/0072
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Apr 1, 2000

    Study Results

    No Results Posted as of Jun 24, 2005